| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | GLAUKOS CORP | 2,603,362 | 43,893,000 | 27.02% | ||
| 2 | COLLEGIUM PHARMACEUTICAL INC COM | 1,887,332 | 34,255,000 | 21.08% | ||
| 3 | AMICUS THERAPEUTICS INC | 2,918,291 | 24,660,000 | 15.18% | ||
| 4 | TOBIRA THERAPEUTICS INC | 2,668,570 | 21,829,000 | 13.44% | ||
| 5 | CIDARA THERAPEUTICS INC | 1,312,258 | 16,666,000 | 10.26% | ||
| 6 | ProNAi Therapeutics, Inc. | 2,186,195 | 14,735,000 | 9.07% | ||
| 7 | IGNYTA INC COM | 950,366 | 6,434,000 | 3.96% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001420506-16-000971, filed 2016.05.13).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
